|
Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting
Seattle Genetics, Inc. today announced that data from two of its antibody-drug conjugate programs, ADCETRIS and ASG-5ME, will be presented at the American Society of Clinical Oncology 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL.
05/16/2012 - 06:08 PM
Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting
SALT LAKE CITY -- Myriad Genetics, Inc. announced today the presentation of a study at the American Society of Clinical Oncology(R) (ASCO) Annual Meeting, including the complete results from a study titled, ...
05/16/2012 - 06:05 PM
Applied Genetics Signs Agreement With The National University Of Mexico (UNAM)
WESTMINSTER, Colo., May 16, 2012 /PRNewswire/ -- GeneThera, Inc. (GTHR.PK) announced today that Applied Genetics, GeneThera's majority owned subsidiary, signed a research and test validation agreement ...
05/16/2012 - 09:30 AM
Interleukin Genetics Reports First Quarter 2012 Financial Results
Interleukin Genetics, Inc. today announced financial and operational results for the first quarter ended March 31, 2012.
05/10/2012 - 04:20 PM
Cancer Genetics IPO Faces Facebook
Cancer Genetics is pursuing a strategy that differs from Facebook's IPO plan, expert says. A Rutherford, N.J.-based start-up developing tools to diagnose cancer is planning to launch an initial public offering this week under the long shadow of Facebook's long-awaited blockbuster IPO.
05/15/2012 - 12:25 PM
Seattle Genetics Reports First Quarter 2012 Financial Results
Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2012. The company also highlighted the ADCETRIS pr
05/08/2012 - 04:05 PM
Seattle Genetics Announces Data from Investigator Trial of ADCETRISâ„¢ in Relapsed Cutaneous T-Cell Lymphoma
Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS in patients with relapsed cutaneous T-cell lymphoma were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.
05/10/2012 - 10:00 AM
Response Genetics, Inc. Announces First Quarter Financial Results
Response Genetics Inc. , , a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated fina
05/10/2012 - 08:30 AM
NewLink Genetics Corporation Reports First Quarter 2012 Financial Results
AMES, Iowa -- NewLink Genetics Corporation , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the ...
05/10/2012 - 05:00 PM
Seattle Genetics pares 1Q loss on Adcetris sales
Seattle Genetics Inc. said Tuesday it took a smaller loss in the first quarter after launching its cancer drug Adcetris. Its revenue for the quarter, however, came in below Wall Street forecasts and its shares dropped 7 percent in extended trading.
05/08/2012 - 04:54 PM
News Feed by
|
